Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation
Xiaoying Ma, Shengyan Dang, Hui Wang, Lei Xia, Ping Ma, Yujuan Qi · 2026
Read Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation by Xiaoying Ma, Shengyan Dang, Hui Wang, Lei Xia, Ping Ma, Yujuan Qi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13311219.txt.
Description
Xiaoying Ma and co-authors, in 2026, offer a review of salidroside, a plant compound from Rhodiola rosea, packed into tiny carriers for triple-negative breast cancer care. This cancer type lacks the usual drug targets and spreads fast.
The review pulls together how the compound attacks cancer cells, in part by driving a form of cell death tied to iron, while sparing normal tissue. It then weighs carrier designs such as polymer and fat-based particles that fix the compound's poor uptake and short life in the body. A marker-guided plan and a three-step path toward clinic use close the review.
Catalog record
| CREATOR | Xiaoying Ma, Shengyan Dang, Hui Wang, Lei Xia, Ping Ma, Yujuan Qi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43595 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |